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ABSTRACT 
Background: The relationship between oxidative stress and osteoarthritis 
(OA) has been widely investigated. Serum malondialdehyde (MDA), nitric oxide 
(NO), and Cu/Zn superoxide dismutase (SOD) levels are useful markers of oxida- 
tive stress. Because of the importance of oxidative stress markers in the patho- 
genesis of OA, treatment might involve modification of these markers to control 
oxidative stress. 
Objective: The aim of this study was to compare the effects of 2 conven- 
tional NSAIDs on markers of oxidative stress in patients with OA of the knee. 
Methods: This 3-week, prospective, randomized, open-label, active- and 
placebo-controlled study was conducted at the Cerrahpasa Faculty of Medicine, 
lstanbul University, lstanbul, Turkey. Adult patients with clinically and radiograph- 
ically diagnosed moderate OA of the knee who were previously untreated were 
enrolled. Patients were randomly assigned to 1 of 3 treatment groups: flurbiprofen 
100 mg PO (tablets) BID, tiaprofenic acid 300 mg PO (tablets) BID, or placebo 
tablets BID. Patients were evaluated using clinical assessment and laboratory test- 
ing before treatment (week 0; baseline) and at the end of week 3. The primary end 
points were the differences in serum MDA, NO, and SOD levels versus placebo. 
Clinical parameters--pain at rest and on motion--were valuated using a 10-cm 
visual analog scale (0 = no pain to 10 = worst pain imaginable). The duration (in 
minutes) of morning stiffness was recorded by patients, using patient diaries. The 
differences between treatment groups were assessed using multivariate analysis. 
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Results: Thirty-nine patients (20 women, 19 men; mean [SD] age, 59.0 [11.3] 
years) were included in the study. Mean serum MDA and NO levels were signif- 
icantly decreased at 3 weeks compared with baseline in the 2 active-treatment 
groups (all, P < 0.001); these values remained statistically similar to baseline in 
the placebo group. Serum SOD levels were increased significantly from baseline 
in the 2 active-treatment groups (both, P < 0.001), but not in the placebo group. 
No significant differences in serum MDA and NO levels were found between the 
group receiving flurbiprofen and that receiving tiaprofenic acid. Serum SOD lev- 
els were significantly higher in the flurbiprofen group compared with the tiapro- 
fenic acid and placebo groups (both, P < 0.01). The mean (SD) score for pain at 
rest was significantly lower at 3 weeks compared with baseline with flurbipro- 
fen and tiaprofenic acid (both, P < 0.001), but not with placebo. The mean score 
for pain on motion was significantly reduced from baseline values only with 
tiaprofenic acid (P < 0.001). The duration of morning stiffness was significantly 
shorter at 3 weeks compared with baseline in all 3 study groups (all, P < 0.001). 
The mean scores for pain on motion and duration of morning stiffness were sig- 
nificantly reduced with tiaprofenic acid compared with placebo (both, P < 0.05). 
The study had some limitations (ie, small sample size, no blinding, the short 
duration of the study, and the weak correlation between serum and synovial 
fluid levels of NO). 
Conclusions: In this comparison of the effects of 3 weeks of treatment with 
flurbiprofen 100 mg BID and tiaprofenic acid 300 mg BID in patients with knee 
OA, both treatments effectively reduced serum MDA and NO levels compared 
with placebo. Only tiaprofenic acid significantly improved pain at rest and on 
motion and duration of morning stiffness compared with placebo. (Curt Ther 
Res Clin Exp. 2005;66:335-344) Copyright © 2005 Excerpta Medica, Inc. 
Re), words: osteoarthritis, malondialdehyde, nitric oxide, superoxide dis- 
mutase, NSAIDs. 
INTRODUCTION 
The relationship between oxidative stress and osteoarthritis (OA) has been 
widely investigated since the 1990s. Malondialdehyde (MDA) is the end-product 
of lipid peroxidation; superoxide dismutase (SOD) is a superoxide radical- 
scavenging enzyme; and nitric oxide (NO) is a free radical synthesized from 
L-arginine by NO synthetase. Serum MDA, NO, and Cu/Zn SOD levels are useful 
markers of oxidative stress. OA is considered a degenerative disease of the car- 
tilage but also involves some synovial inflammationfl 2 Oxidative damage has 
been shown to have an aging effect on the cartilage, which leads to OA in stud- 
ies in humans, animals, and in vitro. 3,4 
Reactive oxygen species (ROS), mostly NO, play a pivotal role in the patho- 
logic process of OA, mainly by contributing to tissue degradation caused by 
inflammation. 1,3,s Although oxidative stress is known to lead to an increased 
risk for OA, the precise mechanism remains unclear. 3
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The potential role of ROS in joint swelling, cellular infiltration, and pain 
remains controversial. 1 Some studies have shown that oxidative stress markers 
play a role in different cellular phases of OA. 4,G Two studies have reported that 
the serum levels of these markers may predict disease activity. 7,s 
NSAIDs have been considered to function as active oxygen inhibitors. How- 
ever, the mechanisms of such inhibitory activity remain unclear. 9
Because of the importance of oxidative stress markers in the pathogenesis of
OA, treatment might involve modification of these markers to control oxidative 
stress. The aim of this study was to determine the efficacy and tolerability of 2 con- 
ventional NSAIDs on markers of oxidative stress in patients with OA of the knee. 
PATIENTS AND METHODS 
This 3-week, prospective, randomized, open-label, active- and placebo-controlled 
study was conducted at the Cerrahpasa Faculty of Medicine, lstanbul Univer- 
sity, lstanbul, Turkey. Sample collection was performed after receipt of written 
informed consent from each subject in accordance with the International 
Federation of Clinical Chemistry and the Declaration of Helsinki. The study was 
approved by the Ethics Committee of Cerrahpasa Medical Faculty. 
Patients aged 218 years with moderate OA of the knee (diagnosed at a physical 
medicine and rehabilitation outpatient clinic using clinical and radiographic 
assessment with American College of Rheumatology criteria 1°) and who had not 
previously received treatment for OA were recruited for the study. Eligible patients 
were asked to participate voluntarily in the study; they were not compensated. 
Patients who had clinically significant laboratory abnormalities related to 
hepatic or renal dysfunction or infectious disease, or who had a history of 
hepatic, renal, or hematopoietic disorders were excluded. Patients who were 
pregnant or breast-feeding also were excluded. 
Within 1 week after screening and enrollment, patients were randomly as- 
signed to 1 of 3 study groups: flurbiprofen 100 mg PO (tablets) BID, tiapro- 
fenic acid 300 mg PO (tablets) BID, or placebo tablets BID. All study drugs were 
self-administered for 3 weeks. Randomization was performed according to age, 
sex, height, weight, body mass index, disease duration, and baseline pain scores 
(at rest and on motion) and duration of morning stiffness. Calculations were 
performed using Unistat version 5.1.03 (Unistat Ltd., London, United Kingdom). 
Patients were assessed clinically using physical examination, including vi- 
tal sign measurements and visual analog scale (VAS) scores and laboratory 
analysis (measurements of serum MDA, NO, and SOD) at baseline and at the end 
of the third week of treatment. 
Preparation of Samples 
The primary end points were the differences in serum MDA, NO, and SOD lev- 
els between the active-treatment groups and the placebo group. Blood samples 
were obtained by using venipuncture, centrifuged at 3000 rpm for 10 minutes at 
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4°C, and stored at 0°C to 4°C until analysis (<3 months). Serum was assayed for 
levels of MDA, NO, and SOD. 
Efficacy 
Pain and Morning Stiffness 
Pain at rest and on motion was evaluated using a 10-cm VAS (0 = no pain to 
10 = worst pain imaginable). 11 The duration of morning stiffness (in minutes) 
was recorded by patients, using patient diaries. 
Laboratory Parameters 
Lipoperoxidation was assessed using the MDA level, which was estimated 
using the thiobarbituric acid method. 12 The serum MDA level was calculated 
using an extinction coefficient (1.56 x 105) and was expressed as nmol/mL. 
Serum NO levels (Iamol/L) were estimated using a calorimetric assay kit 
(Roche Diagnostics, Somerville, New Jersey). 13 
Serum SOD levels (U/mL) were determined using the method described by 
Sun et al, 14 with an assay involving the inhibition of nitroblue tetrazolium reduc- 
tion by superoxide anions. 
Tolerability 
Tolerability was assessed using subject interviews. 
Statistical Analysis 
The calculated power of the trial was 82%. The differences in pain scores 
and laboratory values between the 3 study groups were assessed using multi- 
variate analysis with the Bonferroni and Dunnett ests. P < 0.05 was considered 
statistically significant. 
RESULTS 
Thirty-nine Turkish patients (20 women, 19 men; mean [SD] age, 59.0 [11.3] 
years) were included in the study (Table I). The flurbiprofen, tiaprofenic acid, 
and placebo groups comprised 12, 14, and 13 patients, respectively. No statisti- 
cally significant differences in baseline characteristics were found between the 
3 groups. 
Efficacy 
Laboratory Results 
The mean serum levels of MDA, NO, and SOD before and after treatment are 
shown in Table II. 
Mean (95% CI) MDA levels at 3 weeks of treatment were significantly de- 
creased compared with baseline in the active-treatment groups (flurbiprofen: 
3.13 [ 2.67-4.06] vs 4.57 [ 3.87-5.34] nmol/mL; tiaprofenic acid: 2.86 [ 2.58-3.17 ] vs 
4.05 [3.72-4.46] nmol/mL; both, P < 0.001), but not in the placebo group. No sig- 
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Table I. Demographic characteristics of the study patients (N = 39).* Values are pre- 
sented as mean (SD) unless otherwise noted. 
Flurbiprofen Tiaprofenic Acid Placebo 
Characteristic (n = 12) (n = 14) (n = 13) 
Age, y 57.0 (15.0) 62.0 (9.4) 58.0 (9.7) 
Sex, no. 
Male 6 7 6 
Female 6 7 7 
Country of origin 
Turkey 12 14 1 3 
Height, m 1.55 (0.07) 1.61 (0.01) 1.68 (0.13) 
Weight, kg 72.0 (10.0) 73.0 (9.9) 74.0 (1 3.0) 
BMI, kg/m 2 30.0 (4.1) 28.0 (3.0) 26.0 (4.3) 
Disease duration, y 5.0 (4.3) 5.6 (3.3) 4.7 (3.5) 
Disease severity 
Score for pain at rest t 4.5 (3.6) 3.5 (3.2) 3.0 (2.2) 
Score for pain on motion t 8.3 (1.8) 8.3 (1.8) 6.4 (1.5) 
Duration of morning stiffness, rain 13.1 (3.6) 1 7.0 (12.5) 21.0 (11.1 ) 
BMI = body mass index. 
*No significant differences were found between the 3 groups. 
fAs measured on a 10-cm visual analog scale (0 = no pain to 10 = worst pain imaginable). 
Table II. Oxidative stress markers as measured in the serum before (baseline) and after 
3 weeks of treatment with flurbiprofen (n = 12), tiaprofenic acid (n = 14), 
or placebo (n = 13) in patients with osteoarthritis of the knee. Values are 
presented as mean (95% Cl). 
Marker/Treatment Baseline 3 Weeks P 
MDA, nmol/mL 
Flurbiprofen 4.57 (3.87-5.34) 3.13 (2.67-4.06) <0.001 
Tiaprofenic acid 4.05 (3.72-4.46) 2.86 (2.58-3.17) <0.001 
Placebo 4.02 (3.75-4.39) 3.99 (3.56-4.25) NS 
NO, IJmol/L 
Flurbiprofen 23.18 (21.16-26.22) 18.28 (14.95-28.15) <0.001 
Tiaprofenic acid 23.71 (20.40-25.63) 18.18 (15.63-21.1 9) <0.001 
Placebo 23.26 (19.28-27.78) 22.65 (20.19-24.75) NS 
SOD, U/mL 
Flurbiprofen 22.39 (20.17-24.05) 25.22 (23.26-26.51)* <0.001 
Tiaprofenic acid 23.51 (20.18-25.76) 24.89 (23.50-25.87) <0.001 
Placebo 22.94 (20.28-25.94) 23.71 (21.59-25.28) NS 
MDA = malondialdehyde; NO = nitric oxide; SOD = superoxide dismutase. 
*P < 0.01 versus the tiaprofenic acid and placebo groups. 
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nificant differences in mean MDA levels were found between the active-treatment 
groups and the placebo group at 3 weeks. 
Mean (95% CI) NO levels were significantly decreased at 3 weeks of treatment 
compared with baseline in the active-treatment groups (flurbiprofen: 18.28 
[14.95-28.15] vs 23.18 [21.16--26.22] IJmol/L; tiaprofenic acid: 18.18 [15.63-21.19] 
vs 23.71 [20.4-25.63] IJmol/L; both, P < 0.001), but not in the placebo group. No 
significant difference was found in these levels between the 2 active-treatment 
groups and the placebo group at 3 weeks. 
The mean SOD levels at 3 weeks were significantly higher compared with 
baseline in both active-treatment groups (flurbiprofen: 25.22 [23.26-26.51] vs 
22.39 [20.17-24.05] U/mL; tiaprofenic acid: 24.89 [23.50-25.87] vs 23.51 [20.18- 
25.76] U/mL; both, P < 0.001), but not in the placebo group. At 3 weeks of treat- 
ment, this level was significantly higher in the flurbiprofen group compared 
with the tiaprofenic acid and placebo groups (both, P < 0.01). 
Pain and Morning Stiffness 
After 3 weeks of treatment, he mean (SD) score for pain at rest was signifi- 
cantly decreased from baseline in the flurbiprofen group and the tiaprofenic 
acid group (flurbiprofen: 1.5 [1.9] vs 4.5 [3.6]; tiaprofenic acid: 1.6 [1.7] vs 3.5 
[3.2]; both, P < 0.001) but not in the placebo group (Table III). Mean (SD) scores 
for pain at rest were significantly lower in the flurbiprofen and tiaprofenic acid 
groups compared with that of the placebo group at 3 weeks (both, P < 0.05). No 
significant difference was found between the 2 active-treatment groups. 
Table III. Efficacy parameters  be fore  (baseline) and after 3 weeks of treatment with 
flurbiprofen (n = 12), tiaprofenic acid (n = 14), or placebo (n = 13) in pa- 
tients with osteoarthritis of the knee. Values are presented as mean (SD). 
Parameter/Treatment Baseline 3 Weeks P 
Score for pain at rest* 
Flurbiprofen 4.5 (3.6) 1.5 (1.9) t <0.001 
Tiaprofenic acid 3.5 (3.2) 1.6 (1.7) t <0.001 
Placebo 3.0 (2.2) 2.5 (2.1) NS 
Score for pain on motion* 
Flurbiprofen 8.3 (1.8) 7.3 (2.2) NS 
Tiaprofenic acid 8.3 (1.8) 3.4 (1.7) t <0.001 
Placebo 6.4 (1.5) 5.1 (2.7) NS 
Duration of morning stiffness, min 
Flurbiprofen 1 3.1 (9.6) 3.8 (6.9) <0.001 
Tiaprofenic acid 1 7.0 (12.5) 3.8 (6.9) t <0.001 
Placebo 21.0 (11.1) 15.0 (11.3) <0.001 
*As measured on a 10-cm visual analog scale (0 = no pain to 10 = worst pain imaginable). 
tp < 0.05 versus the placebo group. 
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The mean (SD) scores for pain on motion were significantly lower at 3 weeks 
compared with baseline in the group treated with tiaprofenic acid (3.4 [1.7] vs 8.3 
[1.8]; P< 0.001). In the flurbiprofen group (7.3 [2.2] vs 8.3 [1.8]) and the placebo 
group (5.1 [2.7] vs 6.4 [1.5]), the mean (SD) scores for pain on motion did not 
change significantly. After 3 weeks of treatment, the mean score for pain on 
motion was significantly lower with tiaprofenic acid compared with placebo (P < 
0.05). No significant difference was found between the 2 active-treatment groups. 
The mean (SD) duration of morning stiffness was significantly less at 3 weeks 
compared with baseline in all 3 study groups (all, P < 0.001). After 3 weeks 
of treatment, the duration of morning stiffness was significantly shorter with 
tiaprofenic acid compared with placebo (P < 0.05) (Table III). No significant dif- 
ference was found between the 2 active-treatment groups. 
Tolerability 
Adverse effects (ALEs) were experienced by 3 of the patients receiving flur- 
biprofen (2 patients, mild dyspepsia; 1 patient, moderate headache) and 4 of 
those receiving tiaprofenic acid (3 patients, mild dyspepsia; 1patient, mild mete- 
odsm). None of the patients discontinued the study medication due to an AE. 
DISCUSSION 
Evidence supporting the relationship between oxidative stress markers and the 
pathogenesis of OA is increasing. However, the effects of NSAIDs on this oxida- 
tive cycle are not yet clear. 3,9 In patients with OA, ROSs are produced in greater 
amounts than in healthy individuals, resulting in joint-tissue damage. 2 Mazzetti 
et al 6 found that cells from patients with OA produced higher levels of NO than 
did those from patients with rheumatoid arthritis (RA). However, the harmful 
effects of free oxygen radicals and NO on chondrocytes were found to be more 
prominent in patients with RA, suggesting that NO may play a major role in alter- 
ing chondrocyte function in OA. Also, some studies have suggested that cell 
death in OA-affected chondrocytes i  principally NO-mediated apoptosis. 15,16 
Studies of the effects, other than clinical efficacy, of NSAIDs on ROS are lim- 
ited. Bartosiewicz et al 1T reported that serum MDA level and serum oxidation 
capacity were decreased in patients with OA receiving piroxicam, whereas they 
did not change in patients with RA receiving piroxicam therapy. Gonzalez et al is 
demonstrated that the generation of oxygen by polymorphonuclear cells was 
decreased after 15 days of treatment with diclofenac and aceclofenac in 30 pa- 
tients with severe OA of the knee. In this study, the generation of oxygen 
reached normal values after 180 days. MDA levels in the serum and synovial 
fluid showed significant correlation in patients with RA or OA. However, no sta- 
tistically significant difference in mean (SD) synovial fluid MDA level was found 
between RA (0.17 [0.07] nmol/mL) and OA (0.16 [0.09] nmol/mL). 19 A weak cor- 
relation was found between serum and synovial fluid nitrate/nitrite l vels (r = 
0.35; P = 0.037) in patients with primary knee OA. 2° Total SOD activity was found 
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to be ~3-fold higher in control synovial fluid compared with normal human se- 
rum, but 300-fold lower than in human tissue. 21 
In the present study, we found that tiaprofenic acid and flurbiprofen (to a 
lesser extent) have significant effects on serum levels of MDA, NO, and SOD 
with regard to their clinical efficacy. Because OA is a catabolic process of carti- 
lage tissue, it is crucial to evaluate the proinflammatory c tokines and ROS in 
OA. These data extend our previous observations 22 and suggest an inflamma- 
tory component in OA. In addition, this study may present a new research out- 
come measurement in the evaluation of the therapeutic efficacy of drugs in 
OA. An objective parameter to evaluate patients with OA is still lacking; there- 
fore, biochemical parameters reflecting oxidative stress might be helpful in 
the future assessment of OA. However, there are some conflicting results with 
NSAIDs and their effects on the cyclooxygenase pathway. Pilbeam et a123 found 
that currently available NSAIDs, including flurbiprofen, were unlikely to distin- 
guish completely between the effects mediated by prostaglandin G/H synthase 
(PGHS)-2 or PGHS-1 in their experimental studies. 
Although there were some limitations (ie, small sample size, no blinding, 
short treatment duration, and a weak correlation between serum and synovial 
fluid levels of NO), the results of the present study suggest that tiaprofenic acid 
is more effective in the treatment of the clinical findings of OA compared with 
placebo; the only significant differences in pain on motion and morning stiff- 
ness were between the tiaprofenic acid and placebo groups. Both flurbiprofen 
and tiaprofenic acid significantly reduced pain at rest compared with placebo. 
Similarly, both tiaprofenic acid and flurbiprofen were associated with decreased 
serum levels of oxygen radicals and NO. To date, few clinical studies have 
assessed the role of conventional NSAIDs in decreasing serum oxygen radicals 
and NO in patients with OA. The in vitro effects of NSAIDs and paracetamol n 
oxidative stress-related parameters of human erythrocytes were shown in the 
study by Orhan and Sahin. 24 However, in that study, tiaprofenic acid at a thera- 
peutic dose was associated with a decrease in glutathione S-transferase activity 
and significant inhibition of selenium-dependent glutathione peroxidase at a 
higher dose. 
The fact that spontaneous overproduction of NO has been found in patients 
with OA, but not in patients with RA, might indicate the presence of inflamma- 
tory factors (eg, autocrine cytokines or growth factors in osteoarthritic carti- 
lage 25) or might be due to constitutively increased NO synthase in patients with 
OA. 2G The main reason for the reduced generation of NO in the active-treatment 
groups in the present study might have been the inactivation of the inflamma- 
tory factors and/or NO synthase. 
On the other hand, the increased serum level of SOD in patients with OA 
found in the present study might indicate that oxygen radicals can be degraded 
effectively with flurbiprofen or tiaprofenic acid. In this process, detoxification 
of oxygen radicals might be more effective with flurbiprofen compared with 
tiaprofenic acid based on the findings in the present study. In addition, one 
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pharmacokinet ic  s tudy 9 showed that the hydrogen peroxide level in the serum 
was decreased with flurbiprofen. 
CONCLUSIONS 
In this study of pat ients with knee OA, f lurbiprofen 100 mg BID and t iaprofenic 
acid 300 mg BID were effective in reducing markers  of oxidative stress. Flur- 
biprofen seemed more potent in detoxification of oxygen radicals. However, 
only t iaprofenic acid significantly reduced pain (at rest and on motion) and 
durat ion of morning stiffness compared  with p lacebo in this study. The medica- 
t ions were well tolerated. 
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